Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-517 (Cervarix) Dose-Comparison in Healthy Women
NCT00693966Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 1999
- Primary completion
- Sep 2004
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (4 arms), sponsored by GSK. Primary endpoints: Solicited adverse event rates (including injection site and systemic reactions), Unsolicited adverse event rates and 4 more. Started Oct 1999; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00693966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00693966.